Cited by 172Obstructive Sleep Apnea ResearchSleep and Work-Related FatigueSleep and related disorders

Modafinil for Treatment of Residual Excessive Sleepiness in Nasal Continuous Positive Airway Pressure-Treated Obstructive Sleep Apnea/Hypopnea Syndrome

Black, Jed E., Hirshkowitz, Max·2005·Sleep

Abstract

STUDY OBJECTIVES: Nasal continuous positive airway pressure (nCPAP) usually reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However, even with regular use of nCPAP, some patients experience residual excessive sleepiness. We evaluated the efficacy and safety of the wake-promoting agent modafinil for treating residual excessive sleepiness in nCPAP-treated patients. DESIGN: 12-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. PATIENTS: Patients aged 18 to 70 years diagnosed with obstructive sleep apnea/hypopnea syndrome and having residual excessive sleepiness during nCPAP therapy were eligible. INTERVENTIONS: Once-daily modafinil, 200 mg or 400 mg, or placebo. MEASUREMENTS AND RESULTS: Assessments included the Maintenance of Wakefulness Test, Epworth Sleepiness Scale, Clinical Global Impression of Change, and Functional Outcomes of Sleep Questionnaire. Both doses of modafinil significantly improved mean (SD) sleep latency on the Maintenance of Wakefulness Test at weeks 4, 8, and 12 compared with placebo (week 12: modafinil 400 mg, 15.0 [5.3] minutes; 200 mg, 14.8 [5.3] minutes; placebo, 12.6 [5.8] minutes; P < .0001). The Epworth Sleepiness Scale score decreased more in patients taking modafinil compared with those in the placebo group (week 12: modafinil 400 mg, -4.5 [4.3]; 200 mg, -4.5 [4.7]; placebo, -1.8 [3.5]; P < .0001). At week 12, overall clinical condition improved for 61% and 68% of patients treated with modafinil 200 mg and 400 mg, respectively, versus 37% of placebo-treated patients (P < .001). Modafinil was generally well tolerated and did not adversely affect nighttime sleep or nCPAP use. CONCLUSIONS: These results confirm previous shorter-term controlled trials, indicating modafinil is a useful adjunct therapy for improving wakefulness in patients with residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome who were treated with nCPAP.

Integrity signals

Registry

Crossref · 10.1093/sleep/28.4.464

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Black, J. E., & Hirshkowitz, M.
Affiliations
  • Stanford Medicine (US)
  • Baylor College of Medicine (US)
Corresponding author
Black, Jed E.
Venue
Sleep
Published
2005-04
Volume
28
Issue
4
Pages
464-471
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W144263799
Cited by
172
References
39
Citations by year
2026: 5 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 5 · 2014: 6 · 2013: 8 · 2012: 5
FWCI
10.32
Type
journal article
Language
en
Open access
closed
Locations
  • SLEEP (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
modafinil, obstructive sleep apnea-hypopnea syndrome, nasal continuous positive airway pressure, wakefulness-promoting agents, sleep latency, daytime sleepiness, adjunctive therapy, treatment safety, Epworth Sleepiness Scale, maintenance of wakefulness test, dose comparison, CPAP tolerance, quality of life
MeSH terms
Modafinil, Adolescent, Adult, Aged, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Disorders of Excessive Somnolence, Male, Middle Aged, Surveys and Questionnaires, Severity of Illness Index, Wakefulness, Treatment Outcome, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review